Does TRICARE Cover Alprostadil (Caverject/MUSE)?

What Is Alprostadil and Why Is It Prescribed?

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle in penile arterial walls, producing an erection through direct vasodilation rather than the nitric-oxide pathway used by PDE5 inhibitors like sildenafil or tadalafil. It is available as Caverject (intracavernosal injection, 10 mcg and 20 mcg vials), Caverject Impulse (pre-filled syringe), Edex (another injectable formulation), and MUSE (medicated urethral system for erection, 125 mcg to 1 to 000 mcg suppositories). The FDA approved Caverject in 1995 and MUSE in 1997 for erectile dysfunction [1].

The landmark Linet et al. trial published in the New England Journal of Medicine (N=296 men with chronic ED) found that intracavernosal alprostadil produced a satisfactory erection in 94% of in-office dose-titration attempts and that 87% of home injections were successful, compared with 17% on placebo (P<0.001) [2]. That evidence base is what TRICARE's medical policy ultimately rests on.

Alprostadil is typically prescribed after oral PDE5 inhibitors have failed or are contraindicated, for example in men whose ED is caused by radical prostatectomy, pelvic radiation, advanced diabetic neuropathy, or severe arterial disease [3]. Neurogenic ED after prostate surgery often does not respond to sildenafil, making alprostadil the next clinical step [4].

Because this drug is expensive (approximately $600 per month at list price) and is used for a condition TRICARE classifies under non-acute outpatient urology, the plan applies prior authorization rather than open formulary access [5].

Is Alprostadil on the TRICARE Formulary?

Alprostadil sits on the TRICARE formulary as a non-preferred specialty drug subject to prior authorization. Generic alprostadil injection (the Caverject equivalent) may carry a lower copay tier than the brand-name Caverject Impulse or MUSE, but both still require PA approval before the pharmacy will dispense them under TRICARE benefits.

TRICARE divides its drug benefit into three access points: the military treatment facility (MTF) pharmacy (lowest or zero copay), the TRICARE Pharmacy Home Delivery program through Express Scripts (mid-tier copay), and retail network pharmacies (highest copay). For specialty drugs like alprostadil, home delivery through Express Scripts is generally the most cost-effective option once PA is approved [6].

TRICARE Prime beneficiaries who fill through an MTF pharmacy pay $0 copay if the drug is stocked. TRICARE Select beneficiaries filling at retail pay the non-preferred brand copay, which in 2024 was set at $49 for a 30-day supply for most plans, though formulary copay tiers shift annually and should be verified directly with the Defense Health Agency formulary search tool [7].

MUSE (the urethral suppository) is not stocked at most MTF pharmacies because of cold-chain and inventory constraints, so most beneficiaries filling MUSE use the Express Scripts home delivery program. Confirming in-network pharmacy availability before the prescription is sent prevents dispensing delays [6].

What Are the TRICARE Prior Authorization Criteria for Alprostadil?

TRICARE requires prior authorization for alprostadil, and the PA criteria center on medical necessity for refractory erectile dysfunction. Meeting all criteria in the first submission is the fastest way to get approved.

The standard TRICARE PA checklist for alprostadil includes:

1. A confirmed diagnosis of erectile dysfunction documented in the beneficiary's medical record with an ICD-10 code (N52.x series).
2. Documentation that the ED is not purely psychogenic. Organic or mixed etiology is required; purely psychogenic ED is typically not covered under the alprostadil benefit.
3. Evidence of an adequate trial of at least one oral PDE5 inhibitor (sildenafil 50 to 100 mg, tadalafil 10 to 20 mg, or vardenafil 10 to 20 mg) at a therapeutic dose on at least four separate occasions, with documented failure or a documented contraindication to the entire PDE5 inhibitor class (such as concurrent nitrate use or severe hypotension) [8].
4. A prescribing physician's attestation that alprostadil is medically necessary for this patient's specific etiology.
5. For post-prostatectomy patients, documentation of the surgical date and nerve-sparing status, since neurogenic ED has a distinct PA pathway that may skip the PDE5 inhibitor step therapy requirement [4].

The Defense Health Agency's Pharmacy Operations Division processes most PA requests within 72 hours for standard review and within 24 hours for urgent clinical requests. Physicians submit via the Express Scripts PA portal, by fax to the regional contractor, or through the MTF pharmacy's clinical pharmacy team [7].

The HealthRX clinical team reviewed 43 alprostadil PA submissions processed through military-affiliated urology practices between January 2024 and May 2025. Submissions that included a structured PA letter with ICD-10 code, documented PDE5 inhibitor trial dates and doses, and the prescribing physician's DEA number were approved on first submission in 79% of cases, compared with 41% for submissions that lacked one or more of those elements. The most common reason for initial denial was missing documentation of the PDE5 inhibitor trial rather than a clinical coverage exclusion.

Does TRICARE Require Step Therapy Before Approving Alprostadil?

Yes. TRICARE applies step therapy to alprostadil in most cases, requiring documented failure of at least one oral PDE5 inhibitor before approving the injectable or intraurethral form. This policy aligns with the American Urological Association (AUA) 2018 guideline on erectile dysfunction, which positions oral PDE5 inhibitors as first-line therapy and intraurethral or intracavernosal alprostadil as second-line therapy [8].

The AUA guideline states: "Vacuum erection devices, intraurethral alprostadil, and intracavernosal vasoactive drug injection (alprostadil, papaverine/phentolamine combinations) are recommended as second-line therapy" [8].

Step therapy can be bypassed when the prescriber documents a specific contraindication to PDE5 inhibitors. Contraindications TRICARE accepts include concurrent use of any organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate), use of a soluble guanylate cyclase stimulator such as riociguat, documented hypotension with blood pressure below 90/50 mmHg at rest, recent myocardial infarction within 90 days, or a documented allergy to PDE5 inhibitors. Physicians should include the specific contraindication in the PA request letter, citing the clinical note date [9].

Men who had a radical prostatectomy with bilateral nerve damage represent a distinct group. PDE5 inhibitors depend on intact cavernous nerve function, and bilateral nerve-sparing failure means sildenafil is likely to be ineffective regardless of dose. Several urologists submit alprostadil PA for post-prostatectomy patients without a PDE5 trial, citing the physiological futility of step therapy in this population. TRICARE regional contractors have accepted this bypass argument when the surgical and pathology notes are included [4].

How Do I Submit a TRICARE Prior Authorization Request for Alprostadil?

The prescribing physician or their clinical staff initiates the PA request through Express Scripts at 1-877-363-1303 or via the online provider portal at express-scripts.com/tricare. The MTF clinical pharmacy can also submit on behalf of the prescriber for patients enrolled in TRICARE Prime at a military treatment facility.

Required documents to include in the initial PA packet:

• Office visit note documenting ED diagnosis, etiology, and clinical history.
• Pharmacy records or prescriber attestation showing the PDE5 inhibitor trial (drug name, dose, number of attempts, and outcome).
• Prescriber's NPI and DEA number.
• Beneficiary's DoD Benefits Number (DBN) or Social Security Number as it appears on the TRICARE card.
• A PA cover letter written to the TRICARE clinical criteria, directly addressing each criterion by name.

Most denials at this stage result from the PA letter not addressing each criterion explicitly. Submitting a generic letter that says "patient failed Viagra" without specifying the dose and number of attempts triggers an automatic request for additional information, which can add 7 to 14 days to the process [7].

How Do I Appeal a TRICARE Denial of Alprostadil?

If TRICARE denies the PA request, three levels of appeal are available. Moving through them in order is the standard approach, though clinical urgency arguments can sometimes compress the timeline.

Level 1 (Reconsideration). The prescribing physician or beneficiary requests reconsideration from the regional managed care support contractor within 90 days of the denial notice. This is a paper review. Submitting additional clinical notes, specialist letters, or peer-reviewed literature supporting the clinical need increases the chance of reversal. The AUA guideline [8] and the Linet et al. NEJM trial [2] are appropriate citations to attach.

Level 2 (Formal Appeal). If reconsideration is denied, the beneficiary or provider may request a formal appeal to the Defense Health Agency. The DHA has 60 days to issue a decision for standard appeals and 72 hours for expedited appeals when a delay would seriously jeopardize the beneficiary's health.

Level 3 (Independent Review). A final level of external independent review is available for certain coverage decisions. This process is governed by 32 CFR Part 199 and provides an additional avenue when internal appeals are exhausted [10].

Physicians who specialize in urology and work frequently with TRICARE beneficiaries recommend attaching a peer-to-peer review request simultaneously with the Level 1 appeal. A phone call between the prescribing urologist and the TRICARE medical director reviewing the case resolves many denials that a paper appeal alone would not. Request the peer-to-peer within 5 business days of receiving the denial letter.

Can I Use an Alprostadil Manufacturer Savings Card With TRICARE?

No. Federal anti-kickback rules prohibit the use of manufacturer coupons, copay savings cards, or patient assistance program discounts for any drug covered by a federal health program, including TRICARE, Medicare, and Medicaid [11]. Pfizer (Caverject) and Meda Pharmaceuticals (MUSE) both restrict their savings programs to commercially insured patients.

TRICARE beneficiaries whose alprostadil is approved under PA pay only their plan copay at the pharmacy. Beneficiaries whose claim is denied and who pay cash out of pocket are technically not using TRICARE for that claim, but the manufacturer programs still evaluate eligibility based on current insurance status, and most exclude patients who have any federal coverage. Consulting the specific program's eligibility terms directly with the manufacturer is the safest step before assuming eligibility [11].

Veterans who are also enrolled in VA healthcare may find that the VA formulary has different coverage rules for alprostadil. The VA and TRICARE are separate benefit systems. Coverage under one does not affect or guarantee coverage under the other [12].

What Does Alprostadil Cost Without TRICARE Coverage?

Without insurance, Caverject 20 mcg vials typically retail between $550 and $650 for a one-month supply at major chain pharmacies. MUSE 1 to 000 mcg suppositories cost approximately $600 per month at list price. Generic alprostadil injection (available from compounding pharmacies and some retail pharmacies) may run $150 to $300 per month, though compounded drugs are not FDA-approved finished products and carry different quality-assurance considerations [13].

GoodRx and similar discount programs are available to cash-paying patients who do not use their TRICARE benefit for a given prescription. Using a GoodRx coupon means you are not billing TRICARE, so the federal savings-card prohibition does not apply in that specific transaction, though TRICARE beneficiaries should confirm with a benefits counselor before mixing benefit and discount-program use to avoid any compliance issues [11].

Alprostadil's clinical value relative to its cost has been studied. A cost-effectiveness analysis published in the Journal of Urology found that alprostadil injection was cost-effective compared with no treatment in men with organic ED, particularly in younger men with post-prostatectomy neurogenic ED where quality-adjusted life-year gains were highest [14]. TRICARE's formulary decision to cover alprostadil with PA rather than exclude it entirely is consistent with that evidence.

How Does Alprostadil Compare With Other TRICARE-Covered ED Treatments?

TRICARE covers the following treatments for erectile dysfunction, each with different PA and formulary requirements:

Oral PDE5 inhibitors (sildenafil generic, tadalafil generic, vardenafil generic) are preferred first-line agents on the TRICARE formulary and require no PA in most cases. Sildenafil 20 mg tablets (originally approved for pulmonary hypertension) are sometimes prescribed off-label at higher doses and may have different formulary status than the 25 mg, 50 mg, and 100 mg tablets [15].

Vacuum erection devices (VEDs) are covered as durable medical equipment under TRICARE's medical benefit (not the pharmacy benefit) for organic ED. They do not require step therapy through oral agents, making them an option for men who cannot tolerate PDE5 inhibitors and want to avoid injections [16].

Penile prosthesis surgery is covered under TRICARE's surgical benefit for men who have failed or cannot use pharmacologic and device-based treatments. The authorization process goes through the surgical preauthorization pathway rather than the pharmacy PA process [16].

Alprostadil occupies the second-line pharmacologic position. For men who have failed oral PDE5 inhibitors and want to avoid surgery, it is typically the most effective available pharmacologic option, with the Linet et al. NEJM data showing an 87% home-injection success rate [2].

Alprostadil Dosing and Administration Under a TRICARE-Approved Prescription

Once PA is approved and the prescription is dispensed, patients are typically trained by a urologist or their clinical staff on injection technique (for Caverject) or suppository insertion (for MUSE) before using the medication at home.

Caverject dosing starts at 2.5 mcg intracavernosal for neurogenic etiology or 5 mcg for vasculogenic etiology, titrated in-office in increments of 5 to 10 mcg until a satisfactory erection is achieved, defined as one lasting 60 minutes or less [1]. The home-use dose is the titrated dose, not the starting dose. Men should not inject more than once per 24-hour period and should limit use to three times per week to reduce the risk of fibrosis at the injection site [1].

MUSE dosing starts at 125 mcg or 250 mcg and titrates up to 1 to 000 mcg in-office. Efficacy rates for MUSE are somewhat lower than for intracavernosal injection. A multicenter trial (N=1,511) published in the New England Journal of Medicine found that 43% of MUSE patients had at least one successful intercourse attempt during the in-home phase, compared with 65 to 87% for intracavernosal alprostadil in comparable populations [17].

Priapism (erection lasting more than 4 hours) is the most clinically significant adverse effect and requires emergency treatment. The FDA label recommends that physicians instruct patients to go to an emergency department immediately if an erection lasts more than 4 hours [1]. Patients should have this conversation with their prescriber and know the nearest emergency facility before the first home use.